Andrew Guggenhime, serving as both President and Chief Financial Officer of Vaxcyte, Inc., executed a significant transaction involving the company's equity on June 18, 2026. The executive sold 10,000 shares of Vaxcyte common stock, generating a total transaction value of $530,000. The sale was executed at a specific price point of $53.00 per share.
This disposition of shares was not an ad-hoc decision but rather followed the parameters of a Rule 10b5-1 trading plan. Mr. Guggenhime established this pre-arranged trading framework on March 4, 2026, allowing for the automated execution of trades regardless of subsequent market movements or insider status changes.
Concurrently with the sale, Mr. Guggenhime engaged in a stock option exercise on the same date. He acquired 10,000 additional shares of Vaxcyte common stock by exercising fully vested and exercisable options. The exercise price for these options was set at $5.35 per share, resulting in a direct acquisition cost of $53,500 for the new shares.
Following these dual transactions, Mr. Guggenhime's direct holding in Vaxcyte common stock stands at 104,395 shares. His indirect ownership is maintained through ALG 2025 GRAT HOLDINGS LLC, where he holds an additional 61,850 shares. The structure of this indirect holding involves Mr. Guggenhime acting as the annuitant and trustee of a grantor retained annuity trust. This trust owns 100% of the limited liability company interest within ALG 2025 GRAT HOLDINGS LLC. Furthermore, Mr. Guggenhime retains a portfolio of 236,827 stock options.
The timing of these executive transactions occurs while Vaxcyte shares have experienced notable market performance. The stock has delivered a 54% return over the past year. At the time of reporting, the shares were trading at $51.43, a level slightly below the $53.00 price point at which Mr. Guggenhime executed his sale.
Financial health metrics provide context for the company's operational standing. Analysis indicates that Vaxcyte maintains a balance sheet where cash holdings exceed debt obligations. The company reports a current ratio of 7.49, a figure that reflects substantial financial flexibility for a biotechnology firm. This liquidity position supports ongoing operational demands.
Operational developments at Vaxcyte include significant milestones in its clinical pipeline. The company has completed enrollment in two Phase 3 clinical trials for its 31-valent pneumococcal conjugate vaccine candidate, designated as VAX-31. The first trial, OPUS-1, enrolled approximately 4,000 participants. The second trial, OPUS-2, included around 1,300 participants. These studies are designed to support a planned Biologics License Application submission to the U.S. Food and Drug Administration.
Further advancing its pipeline, Vaxcyte announced the dosing of the first participant in a Phase 1 study for VAX-A1. This candidate targets Group A Streptococcus. The company projects the release of topline data from this Phase 1 study in the latter half of 2027.